TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

Jacob S, Mayer EL, Kacik N, Storniolo AM, Isaacs C, Mayer I, Stearns V, Nanda R, Nangia J, Chien AJ, Moasser M, Melisko M, Wabl C, Muzikansky A, Geradts J, Dillon DA, Park BH, Krop I, Wolff AC, Kochupurakkal B, Shapiro GI, Rugo HS. TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer. ESMO Open. 2026 Apr; 11(4):106063.